ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2358

Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials

Margaux MALAURIE1, Arnaud Constantin 2, Yannick Degboé 1, Adeline Ruyssen-Witrand 3 and Thomas Barnetche 4, 1CHU TOULOUSE, TOULOUSE, France, 2CHU TOUOUSE, TOULOUSE, France, 3Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, 4FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cardiovascular disease and meta-analysis, drug safety, Janus kinase (JAK), Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis (RA) initiating a Janus kinase inhibitor (JAKi).

Methods: Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to February 2019. Randomised controlled trials (RCTs) of JAKi for the treatment of rheumatoid arthritis were included. Two investigators independently extracted MACEs or VTEs reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or VTEs.

Results: From 205 references screened, 26 articles were selected, and 3 articles were added by manual searches. Accordingly 30 RCTs were included in the meta-analysis. No statistically significant difference was observed in MACE (Figure 1) or VTE incidences (Figure 2) in patients receiving any of the JAKi compared to the placebo group. A numeric imbalance was observed in the baricitinib group with 7 VTEs (688 P-Y) compared with none in the placebo group (452 P-Y), with 0,01 -0,00 to 0,02 risk difference, which is not statistically significant. A numeric imbalance was also observed in the upadacitinib group with 6 VTEs (611 P-Y) compared to 1 VTE in the placebo group (440 P-Y), with 0,01 -0,00 to 0,02 risk difference, which is not statistically significant neither.

Conclusion: This MA of 30 RCTs did not reveal any statistically significant change in the short-term risk of MACEs or VTEs in patients with RA initiating a JAKi. Data from the long-term extension phases of these RCTs, from studies designed to compare JAKi to bDMARDs with respect to MACEs or VTEs and from the long-term follow-up of patients included in JAKi registries are required to further characterise the risk of MACEs or VTEs in patients with RA treated with JAKi.


MACE_JAKi vs PBO_V2

Difference in the risk of MACEs in RA patients treated with JAKi compared with the placebo in RCTs.


ETE_JAKi vs PBO_V2

Difference in the risk of VTEs in RA patients treated with JAKi compared with the placebo in RCTs.


Disclosure: M. MALAURIE, None; A. Constantin, Novartis, 8, Pfizer, 5, Sanofi, 5, SANOFI, 8, UCB, 5, 8; Y. Degboé, None; A. Ruyssen-Witrand, None; T. Barnetche, None.

To cite this abstract in AMA style:

MALAURIE M, Constantin A, Degboé Y, Ruyssen-Witrand A, Barnetche T. Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/short-term-risk-of-major-adverse-cardiovascular-events-or-venous-thrombo-embolic-events-in-patients-with-rheumatoid-arthritis-initiating-a-janus-kinase-inhibitor-a-meta-analysis-of-randomised-control/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/short-term-risk-of-major-adverse-cardiovascular-events-or-venous-thrombo-embolic-events-in-patients-with-rheumatoid-arthritis-initiating-a-janus-kinase-inhibitor-a-meta-analysis-of-randomised-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology